Morgan Stanley Cuts Omada Health (NASDAQ:OMDA) Price Target to $30.00

Omada Health (NASDAQ:OMDA) had its price target reduced by Morgan Stanley from $32.00 to $30.00 in a research note issued to investors on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Other analysts have also recently issued reports about the company. Weiss Ratings reissued a “sell (d)” rating on shares of Omada Health in a research note on Thursday, January 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of Omada Health in a research report on Thursday, January 22nd. Barclays cut their price objective on Omada Health from $22.00 to $17.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Evercore boosted their target price on Omada Health from $27.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Finally, BMO Capital Markets started coverage on Omada Health in a report on Thursday, November 13th. They set an “outperform” rating and a $27.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $22.90.

Omada Health Stock Up 3.3%

Shares of OMDA opened at $14.05 on Friday. The stock has a market capitalization of $813.64 million and a P/E ratio of -56.20. Omada Health has a twelve month low of $10.28 and a twelve month high of $28.40. The firm has a fifty day simple moving average of $14.03 and a two-hundred day simple moving average of $18.65.

Omada Health (NASDAQ:OMDA) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.12. The firm had revenue of $75.85 million during the quarter.

Insider Activity

In other Omada Health news, CEO Sean P. Duffy sold 40,796 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $15.95, for a total transaction of $650,696.20. Following the transaction, the chief executive officer owned 126,644 shares in the company, valued at approximately $2,019,971.80. This represents a 24.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Wei-Li Shao sold 5,618 shares of the stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $16.13, for a total value of $90,618.34. Following the completion of the transaction, the president directly owned 69,079 shares of the company’s stock, valued at $1,114,244.27. This represents a 7.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 276,893 shares of company stock valued at $4,336,787 over the last 90 days.

Institutional Investors Weigh In On Omada Health

Several hedge funds have recently made changes to their positions in OMDA. Quarry LP purchased a new position in Omada Health during the fourth quarter valued at $29,000. TD Waterhouse Canada Inc. bought a new position in shares of Omada Health in the 4th quarter worth about $32,000. Raymond James Financial Inc. bought a new position in shares of Omada Health in the 2nd quarter worth about $32,000. Strs Ohio purchased a new position in Omada Health during the 3rd quarter valued at about $38,000. Finally, Inlight Wealth Management LLC purchased a new position in Omada Health during the 4th quarter valued at about $45,000.

Key Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q4 results beat consensus — Omada reported $0.08 EPS vs. a ($0.04) consensus and $75.85M revenue, with year-over-year revenue growth and positive adjusted EBITDA and Q4 net income, signaling improving profitability. GlobeNewswire: Q4 & Full-Year Results
• Positive Sentiment: Company set a 2026 revenue-growth target (~22%) and is expanding its care offerings (new GLP-1 and cholesterol programs), which underpin upside to recurring revenue and member monetization. Seeking Alpha: 22% Growth Target & New Programs
• Positive Sentiment: Product launch — Omada announced “GLP‑1 Flex Care,” a program that enables employer-sponsored access to GLP‑1 obesity care while limiting employer drug-cost exposure, which could broaden sales channels and employer uptake. GlobeNewswire: GLP-1 Flex Care
• Positive Sentiment: Goldman Sachs maintained a Buy rating with a $26 target, citing a profitability inflection and double-digit growth outlook — a supportive institutional endorsement. TipRanks: Goldman Sachs Note
• Neutral Sentiment: Morgan Stanley trimmed its price target slightly (from $32 to $30) but kept an Overweight rating — still implies significant upside, so the impact is muted. Benzinga: Morgan Stanley PT
• Negative Sentiment: Several firms cut price targets — Canaccord lowered its target to $22 (still Buy), BMO cut to $18 (Outperform), and Barclays reduced its target to $17 — these cuts can create downward pressure despite bullish ratings. Benzinga: Canaccord / BMO notes TickerReport AmericanBankingNews: Barclays

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.